Category: Uncategorized

Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”

Back

Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”

Read More

Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger

Back

Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger

Read More

Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering

Back

Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering

Read More

Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements

Back

Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements

Read More

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Back

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Read More

Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split

Back

Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split

Read More

Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq’s Stockholders’ Equity Standard

Back

Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq’s Stockholders’ Equity Standard

Read More

Salarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies

Back

Salarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies

Read More

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board

Back

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board

Read More

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses

Back

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses

Read More